A long-time darling of venture capital, the gastrointestinal sector has yet to meet expectation of VCs who wagered on technologies to treat gastroesophageal reflux disease, Barrett’s esophagus and even obesity. But some notable acquisitions – including Covidien Ltd.’s purchase of privately held Barrx Medical Inc.– may present a ray of hope for investors in GI companies. [See Deal]
Over the past six years, venture capitalists have invested close to $500 million in privately held GI players. (See Exhibit...